Breastcancer.org· @Breastcancerorg · X·· 9 小时前评分70
正文 · 机器翻译
FOURLIGHT-1 试验的最新研究结果在 #ESMO26 上公布，结果提示 atirmociclib 联合 Faslodex 可能帮助 HR+、HER2 阴性转移性乳腺癌患者延长生存期，同时避免癌症生长。
🔗 了解更多：https://bit.ly/4ewhPCh
#BreastCancer #BreastCancerResearch #ESMO26 #InsightsbyESMO #ClinicalTrials #Metavivor
34 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.org来源：Breastcancer.org · x.com